Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 3:36 PM
Ignite Modification Date:
2025-12-25 @ 1:48 PM
NCT ID:
NCT05263492
Group ID:
EG000
Title:
Pembrolizumab & Lenvatinib
Description:
Lenvatinib, 20 mg administered orally (PO) once daily (QD) during each 21-day cycle, and Pembrolizumab, 200 mg administered by intravenous (IV) infusion on day 1 of each 21-day cycle.
Lenvatinib: Lenvatinib once a day by mouth every day
Pembrolizumab: Pembrolizumab through a needle or tube in a vein (intravenously, IV) every 3 weeks.
Deaths Number Affected:
2
Deaths Number At Risk:
None
Serious Number Affected:
0
Serious Number At Risk:
4
Other Number Affected:
4
Other Number At Risk:
4
Study:
NCT05263492
Results Section:
NCT05263492
Adverse Events Module:
NCT05263492